All posts by Chris

After Cancer, Cancer Survivors

Cancer Super-Survivors Give Us All Hope

Cancer Survivor
Cancer Survivor

Today’s array of immunotherapy  treatments are offering cancer victims something they’ve been robbed of for some time– a fighting chance. Read on to discover more about super-survivors and the treatments that are not only putting immunotherapy in the spotlight, but transforming the future of cancer treatment.

Super-survivor stats:

  • Joseph Rick
    Rick’s advanced melanoma metastasized throughout his body. Years of the side effects of chemo and radiation left a lasting impression, but did not cure his cancer. When doctors gave up hope, Rick turned to a trial vaccine immunotherapy. A year later his tumors had shrunk 50 percent, and after three years he experienced remission.
  • Tom Telford
    A tumor on Telford’s small intestine spread to his liver and kidneys following surgery and chemo, however Telford is still alive nine years later following treatment with immunotherapy.
  • Richard Logan
    Logan’s skin melanoma metastasized to his lung and liver. His cancer has been stabilized five years following treatment with checkpoint inhibitors, a form of immunotherapy.

Treating the immune system, not cancer:
Harnessing the power of the immune system, immunotherapy is charting new territory. It offers a chance at long-term survival, particularly in advanced cancers, with developments in treatment technology such as:

  • Checkpoint inhibitors
    Certain immune system components can prevent immune system warriors, T-cells, from attacking tumors. Checkpoint inhibitors block these components, putting T-cells back in the fight.
  • T-cell therapy
    This therapy involves genetically modifying certain T-cells outside the body, creating “CAR T cells”, which are then re-infused back into the body to attack targets on the surface of cancer cells.
  • And many more therapies both in use and under investigation.

Want to be a super-survivor? Contact Issels® today.

Alternative Cancer Treatment, Immunotherapy

One Fight Against Cancer – A Story of Immunotherapy

Fighting Cancer With Immunotherapy
Fighting Cancer With Immunotherapy

When 36-year-old real estate agent Sue Scott’s cervical cancer was found to have not only returned, but spread to her lymph nodes just a few short months after she believed it was beaten, Scott put on her boxing gloves and turned to immunotherapy.

Limited options
Having previously received the maximum amount of radiation possible in her lifetime and with chemo unable to prevail against Sue’s metastatic cervical cancer, she turned to the surgeon who previously treated her mother’s uterine cancer with a hysterectomy.

An experimental approach
Following in the footsteps of her mother, Sue also underwent a hysterectomy, as well as the removal of cancerous lymph nodes and organs. The surgeon then proceeded to tell her about an immunotherapy trial at the NIH Clinical Center in Bethesda that could give her a chance.

Immunotherapy at work
In immunotherapy, the patient’s own immune system is used to attack tumors, offering hope to metastatic cancer sufferers who have little left in the way of treatment options. There are multiple forms of immunotherapy available. Sue’s treatment involved T-cell therapy in which tumor-fighting immune cells are isolated, grown in a lab, and then re-infused into the body. The tumor is then removed and a regimen of intense chemo follows.

Promising results
A month after the conclusion of Sue’s treatment, CT scans revealed significant shrinkage to the 7 tumors throughout her body. Two months following treatment she was cancer-free, and appears to be in remission nearly three years to the day of her diagnosis.

Are you looking for alternative cancer treatments that give you the chance at the same promising results Sue experienced? Contact Issels® today to learn more.

Alternative Cancer Treatment, Immunotherapy

Immunotherapy: Cancer’s Kryptonite

image of cells
Finding a way to pierce the shield that cancer cells use to hide from the body’s immune system attackers.

As noted in our previous post, immunotherapy is redefining cancer treatment and providing answers to questions that have long puzzled cancer researchers. Of critical importance has been finding a way to pierce the shield that cancer cells use to hide from the body’s immune system attackers. In what is being heralded as a new era in cancer treatment, researchers are finding in personalized immunotherapy the key to unleashing the immune system’s super powers and smashing through cancer’s shields.

In studying the cancer genome, scientists have discovered that some cancer cells are able to thwart immune response by co-opting for their own use the molecular mechanisms that govern cell communication and turn on and off certain cell functions. In effect, these cancer cells seem able to disguise their biological signature in such a way that immune system defenders no longer identify them as invaders. However, by augmenting the natural power of the body’s immune system, immunotherapy is proving to be highly effective in unmasking these disguises and allowing immune system defenders to penetrate cancer’s shields and attack.

Top U.S. cancer researchers described the results being achieved with immunotherapy as “amazing,” “a game-changer” and “a watershed moment,” in interviews with the New York Times. According to the Times, “This period will be viewed as an inflection point, a moment in medical history when everything changed.”

A pioneer in the field of immunotherapy Dr. Josef Issels opened his first alternative cancer treatment center in Germany more than 60 years ago. We were among the first to demonstrate the success of immunotherapy in achieving long-term remissions of advanced and treatment-resistant cancers.

Alternative Cancer Treatment, Immunotherapy

Immunotherapy Is Redefining Cancer Treatment

Flask containing a liquid.
Immunotherapy is redefining cancer treatment.

New discoveries in the field of immunotherapy are providing answers to a question that has bedeviled cancer researchers for more than a century: How are cancer cells able to evade the immune system and survive in the body? Advancements in genetic and cellular research are providing scientists with new insights into the unique ways cancer cells interact with the body’s immune system.

The immune system is the body’s first line of defense against disease, bacteria, viruses, abnormal cells and other harmful agents that invade and attack the body. When the body is attacked, the immune system mobilizes an army of white blood cells, including specialized T-cells and Natural Killer Cells, the Seal Team 6 of the immune system army.

In most cases, the immune system is extremely effective in hunting down and killing harmful invaders; but cancer cells seem to have a unique ability to clothe themselves in a shield of invisibility that allows them to evade immune system defenders. How cancer cells are able to do this is a question that has puzzled cancer researchers for more than a century.

Complicating the puzzle is the fact that when cancer cells are placed in a Petri dish and exposed to white blood cells in the sterile environment of research laboratories, the white blood cells immediately attack and kill the cancer cells. So why doesn’t this happen in the human body? How are cancer cells able to shield themselves from the immune system and how can the immune system break through that shield? Researchers are finding the answers in integrated immunotherapy.

Next time: Immunotherapy: cancer’s kryptonite

Alternative Cancer Treatment, Cancer Research

Dendritic Cell Vaccines Are Changing Cancer Treatment Focus in the U.S.

1 Comment
Cancer Vaccine
Cancer Vaccine

“When Angelina Jolie learns she has a breast cancer gene, we don’t know what else to do, so we cut her breasts off,” Dr. Susan Love, president of the Dr. Susan Love Research Foundation, recently told USA Today. “We have to be looking for the cause.  I worry that we don’t, that we’re paying too much attention to the treatment, which comes with a huge cost.”

Interviewed about the new U.S. push to develop a breast cancer vaccine, Dr. Love was voicing the frustration many feel about the focus of U.S. cancer research and treatment. Appearing to lag their European peers, U.S. cancer researchers are only now recognizing the importance of immunotherapy in treating cancer. Jumping on the bandwagon, many U.S. university centers are exploring immunotherapy’s holistic, non-toxic approach to cancer treatment and beginning to offer trials of dendritic cell vaccines. Issels already has more than half a century of clinical experience with immunotherapy and years of proven experience using dendritic cell vaccines.

At the University of Pennsylvania, doctors recently began testing personalized cancer vaccines made with the patient’s own immune cells. As noted in the USA Today article, in the Pennsylvania test women with an early cancerous condition called ductal carcinoma in situ (DCIS) are being inoculated with an immunotherapy vaccine following surgical removal of breast tumors. It is hoped that the vaccination will prevent tumor recurrence; but trial participants will have to wait years before they know if the vaccine is effective.

At Issels you don’t have to wait. We already have a unique track record of long-term cancer remission results using cancer vaccines in integrative immunotherapy.

Alternative Cancer Treatment, Cancer Research

Tumor Microenvironment Holds Key to Cancer Prevention and Treatment

Laboratory microscope
Cancer Advancements at the Tumor Microenvironment Level

The importance the tumor microenvironment plays in the development and metastasis of cancer is turning a new page in cancer research, treatment and prevention. As scientists work to unlock cancer’s genetic code, they are developing new understandings into how cancer cells communicate and the switches that turn tumor development on and off. At the core of many new discoveries is the complex relationship between cancer tumor cells and the microenvironment in which they develop.

European cancer researchers were early to recognize the importance of the tumor microenvironment. According to a 2010 Italian study, “Microenvironment components play a pivotal role in the regulation of the angiogenic switch and in cancer progression.” (Angiogenesis is the growth of new blood vessels necessary for tumor growth.) The Italian study concluded:

“The comprehension of biological and molecular mechanisms involved in the relationship between tumor cells and the microenvironment could unveil new therapeutic and preventive approaches to cancer.”

Within two years, European cancer researchers were conducting clinical applications of cancer therapies that targeted the tumor microenvironment, which a 2012 Belgian study called “an essential ingredient of cancer malignancy.” According to researchers at the Laboratory of Tumor and Development Biology at the University of Liège:

“The malignant features of cancer cells cannot be manifested without an important interplay between cancer cells and their local environment. … Thus in the clinical setting the targeting of the tumor microenvironment to encapsulate or destroy cancer cells in their local environment has become mandatory.”

One thing that distinguishes Issels Integrated Oncology from other U.S. cancer treatment programs is our use of integrative immunotherapy to specifically target the cancer tumor microenvironment.